- Nektar Therapeutics (NASDAQ:NKTR) has received FDA clearance for an Investigational New Drug (IND) application for its investigational IL-2 pathway agent, bempegaldesleukin (BEMPEG, NKTR-214), to be evaluated in a Phase 1b clinical study in adult patients with mild COVID-19 infection.
- The study is designed to evaluate whether BEMPEG's ability to stimulate lymphocyte production could improve treatment regimens for COVID-19 patients. Enrollment is planned to start in early November.
- Primary and secondary endpoints of the study include change over time in absolute lymphocyte counts and measurements of clinical progression based upon the WHO Clinical Progression Scale.
- The trial will enroll up to three cohorts of ten patients each, with the aim of evaluating safety and tolerability and to identify the recommended dose for future studies.
- The company held an analyst and investor conference call today at 8:30 a.m. EDT.
- https://seekingalpha.com/news/3626319-nektar-therapeutics-on-go-study-of-bempegaldesleukin-in-covidminus-19
Tuesday, October 27, 2020
Nektar Therapeutics on go with study of bempegaldesleukin in COVID-19
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.